#USA #Boulder #HCM #Edgewise Therapeutics #EDG-7500

Edgewise Therapeutics Reports Positive Phase 2 Results for EDG-7500 in Hypertrophic Cardiomyopathy

On June 16, 2026, Edgewise Therapeutics, Inc., a pioneer in muscle disease biopharmaceuticals, announced compelling top-line results from the 12-week Phase 2 CIRRUS-HCM trial of its investigational drug EDG-7500. This trial specifically targeted both obstructive (oHCM) and nonobstructive (nHCM) forms of hypertrophic cardiomyopathy (HCM). As the most prevalent genetic heart disorder, HCM presents challenges including reduced quality of life and heightened risks of heart failure.

Overview of EDG-7500

EDG-7500 is a unique oral agent that acts as a selective cardiac sarcomere modulator. Its design aims to alleviate the symptoms of HCM without hindering systolic function—making it an attractive option for patients who suffer from this debilitating condition. Throughout the trial, no significant relationships were observed between the drug's concentrations and left ventricular ejection fraction (LVEF), helping to underscore its potential safety profile.

Trial Findings

The CIRRUS-HCM trial—with over 700 echocardiograms conducted—showed substantial improvements across various measures of heart function, symptoms, and overall patient health. Both forms of HCM saw clinically meaningful enhancements in key measures. In patients with oHCM, over 90% noted improved hemodynamic responses, alongside a 90% reduction in left ventricular outflow tract gradient (LVOT-G). Notably, 74% of patients achieved either normalization of NT-proBNP levels or a reduction of 50% or more from baseline, pointing to significant changes in heart failure severity.

In patients diagnosed with nHCM, similar positive outcomes were recorded. Participants showed an impressive average 65% reduction in NT-proBNP levels. Other improvements included a 13-point boost in the Kansas City Cardiomyopathy Questionnaire Overall Summary Score (KCCQ-OSS), with 64% displaying at least one class improvement in the New York Heart Association (NYHA) functional classification.

Safety Profile

Safety assessments revealed that EDG-7500 was generally well tolerated among the 53 participants in the trial. Mild to moderate adverse effects were recorded, with no alarming reductions in LVEF or significant new safety signals identified. Only two events of new-onset atrial fibrillation were reported, both deemed unrelated to the administration of the study drug.

Statements from Leadership

Kevin Koch, Ph.D., President and CEO of Edgewise, noted, "From the outset, our aim was to develop a cardiovascular therapy that mitigates the risks associated with current treatment options. These Phase 2 results represent a critical triumph for both Edgewise and the HCM community, emphasizing the unique therapeutic approach of EDG-7500."

Dr. Matthew Martinez, president of the HCM Society, also commented on the encouraging data, stating that the outcome further validates the drug's differentiated profile, especially in patients with nHCM where the preservation of systolic function is crucial.

Future Directions

The positive outcomes from this Phase 2 trial lay a strong foundation for advancing EDG-7500 into Phase 3 clinical development, which is set to kick off in the fourth quarter of 2026. Furthermore, Edgewise Therapeutics is set to hold a live webcast to delve deeper into these findings, featuring insights from leading experts in cardiology.

Conclusion

With HCM affecting approximately 1 in 500 individuals, the necessity for effective therapies remains paramount. Edgewise Therapeutics continues to pave the way in developing strategic treatment options that address the pressing needs of patients suffering from this complex disorder. As the company progresses toward later clinical trials, anticipation builds within both the medical community and patients for a potential breakthrough in the management of hypertrophic cardiomyopathy.